167 related articles for article (PubMed ID: 17311349)
21. Rituximab in the treatment of acquired hemophilia.
Stachnik JM
Ann Pharmacother; 2006 Jun; 40(6):1151-7. PubMed ID: 16735671
[TBL] [Abstract][Full Text] [Related]
22. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
23. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus.
ten Cate R; Smiers FJ; Bredius RG; Lankester AC; van Suijlekom-Smit LW; Huizinga TW; Egeler RM
Rheumatology (Oxford); 2004 Feb; 43(2):244. PubMed ID: 14739467
[No Abstract] [Full Text] [Related]
25. Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency.
Mahévas M; Le Page L; Salle V; Cevallos R; Smail A; Duhaut P; Ducroix JP
Am J Hematol; 2006 Aug; 81(8):645-6. PubMed ID: 16823831
[No Abstract] [Full Text] [Related]
26. Rituximab use in pediatric autoimmune diseases: four case reports.
Polido-Pereira J; Ferreira D; Rodrigues AM; Nascimento C; Costa P; Almeida M; da Silva JE; Simão C; Stone R; Ramos F; Neto A; da Costa JC; Melo-Gomes J; Gomes-Pedro J; Viana-Queiroz M; Canhão H; Fonseca JE
Ann N Y Acad Sci; 2009 Sep; 1173():712-20. PubMed ID: 19758220
[TBL] [Abstract][Full Text] [Related]
27. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
28. Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Citak EC; Citak FE
J Trop Pediatr; 2011 Feb; 57(1):71-2. PubMed ID: 20463085
[No Abstract] [Full Text] [Related]
29. Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Diwakar L; Gorrie S; Richter A; Chapman O; Dhillon P; Al-Ghanmi F; Noorani S; Krishna MT; Huissoon A
J Clin Pathol; 2010 Mar; 63(3):275-7. PubMed ID: 20203231
[TBL] [Abstract][Full Text] [Related]
30. Rituximab treatment for symptomatic chronic ITP.
Tamminga RY; Bruin MC
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):714-6. PubMed ID: 16933264
[TBL] [Abstract][Full Text] [Related]
31. Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura.
Stübgen JP
J Neurol Sci; 2010 Jan; 288(1-2):178-81. PubMed ID: 19897212
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in children with idiopathic thrombocytopenic purpura: does it really work?
Russo G; Licciardello M; La Spina M
Eur J Pediatr; 2004 Sep; 163(9):569. PubMed ID: 15243812
[No Abstract] [Full Text] [Related]
33. [Monoclonal antibody therapy for disorders of hemostasis and coagulation].
Nishimura S; Ishida T; Imai K
Nihon Rinsho; 2002 Mar; 60(3):525-30. PubMed ID: 11904968
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
[TBL] [Abstract][Full Text] [Related]
36. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
37. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
Benedetti L; Franciotta D; Beronio A; Cadenotti L; Gobbi M; Mancardi GL; Schenone A; Tartaglione A
Muscle Nerve; 2008 Aug; 38(2):1076-7. PubMed ID: 18642360
[No Abstract] [Full Text] [Related]
38. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
Introna M; Golay J; Barbui T
Haematologica; 2003 May; 88(5):482-4. PubMed ID: 12745265
[No Abstract] [Full Text] [Related]
39. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
Kuwana M; Iki S; Urabe A
Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G
Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
